Retrospective study of anti-GD2 Immunotherapy

Not Applicable

• Conditions: euroblastoma; Neuroblastoma

• Registration Number: JPRN-jRCT1050230140
• Lead Sponsor: itani Chika

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-03
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Cases falling under (i) or (ii)
(i) Cases with newly diagnosed neuroblastoma who was started GD2 immunotherapy between September 1, 2021 and December 31, 2022 within 1 year of transplantation (autologous or allogeneic)
(ii) Cases with recurrent or relapsed neuroblastoma who was started GD2 immunotherapy between September 1, 2021 and December 31, 2022.

Exclusion Criteria

none

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
GD2 Immunotherapy Completion by Allogeneic Transplant History

Secondary Outcome Measures

Name	Time	Method
Adverse Events of GD2 Immunotherapy <br>Drug Dose Changes in GD2 Immunotherapy<br>Event free survival